세계의 의약품 약물전달 시장 : 투여 경로별, 용도별, 사용 시설별, 지역별 - 예측(-2029년)

The global pharmaceutical drug delivery market is projected to reach USD 2,546.0 billion by 2029 from USD 1,949.4 billion in 2024 at a CAGR of 5.5% during the forecast period. The rapid growth in the geriatric population globally and the significant rise in the patients with chronic diseases are expected to boost the demand for pharmaceutical drug delivery market. Moreover, gradual rise in utilization of home care and self administration is likely to support the market growth. Advancements in drug delivery technology, new product launches, robust pharmaceutical R&D investments by key companies and government policies, investments in healthcare infrastructure, and initiatives to enhance the accessibility and affordability of drug delivery products is anticipated to fuel the market growth.

"The injectable drug delivery segment of pharmaceutical drug delivery market to grow with the highest CAGR during the forecast period."

Based on the pharmaceutical drug delivery market, the injectable drug delivery segment is anticipated to grow at significant rate during forecast period. Due to increasing prevalence of chronic disease. Injectables are used in many therapeutic areas, such as hormonal disorders, oncology, autoimmune diseases, and orphan diseases. The injectable route is a promising alternative over oral drug delivery.Moreover it also maximize patient compliance, and reduce the frequency of dosage administration .Also, Due to increased preference in self-administration and home care, there has been significant development and advancement in injectables that have helped in minimizing the exposure of needles as well as the pain associated with them.These factors are fostering the growth of injectable drug delivery at higher pace.

"The Cancer segment to capture the largest market share of pharmaceutical drug delivery market."

Based on application the Pharmaceutical drug delivery market are segmented into infectitous diseases, cancer, autoimmune disease, diabetes other disease indications The cancer segment held the largest market share during the forecast period. Cancer forms a key therapeutic application segment for drug delivery technologies. Pharmaceutical drug delivery technologies are widely used in various therapies, such as chemotherapy, hormone therapy, target therapy, and immunotherapy. The incidence of cancer has surged rapidly across the globe. According to the WHO, in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. Owing to this, companies are increasingly focusing on developing novel medicines for cancer; this is expected to drive the growth of this therapeutic segment.

"North America accounted for the largest share of the pharmaceutical drug delivery market by region."

The global pharmaceutical drug delivery market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest regional market for pharmaceutical drug delivery products and services , whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.

The largest share of North America can be attributed to the high disease burden of chronic disease contributing to a larger pool of patients requiring pharmaceutical drug delivery products. The presence of numerous potentialphaemaceutical giants ,surge in medical procedures , and favorable reimbursement policy in the region is likely to promote the growth of pharmaceutical drug delivery market in North America.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-35%, Tier 2-45%, and Tier 3- 20%
• By Designation: C-level-35%, Director-level-25%, and Others-40%
• By Region: North America-45%, Europe-30%, Asia Pacific-20%, Latin America-3%, and the Middle East & Africa-2%

The major players operating in the pharmaceutical drug delivery market market are Johnson & Johnson services, inc (US), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US),,), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Sanofi (France), Bayer AG (Germany), Amgen, Inc. (US).

Research Coverage

This report studies the pharmaceutical drug delivery market based on pharmaceutical drug delivery, route of administration, application, facility of use and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

• Analysis of Key divers (increasing prevalence of chronic disease, technological advancement in pharmaceutical drug delivery technologies, new product launches, growing investments in pharmaceutical R&D), restraints (high cost of development, risk of needlestick injuries) , Opportunities (emerging markets, gradual shift towards homecare and self administration) , Challenge (pricing pressure)
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the pharmaceutical drug delivery market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the pharmaceutical drug delivery market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pharmaceutical drug delivery market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 MAJOR STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY RESEARCH
    • 2.1.2.1 Insights from primary experts
    • 2.1.2.2 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET SHARE ESTIMATION
• 2.4 STUDY ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW
• 4.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE AND COUNTRY
• 4.3 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 MARKET DYNAMICS
  • 5.1.1 DRIVERS
    • 5.1.1.1 Rising prevalence of chronic diseases
    • 5.1.1.2 Technological advancements and product launches
    • 5.1.1.3 Rising investments in pharmaceutical R&D
    • 5.1.1.4 Growing emphasis on patient convenience
    • 5.1.1.5 Government initiatives to boost affordability
  • 5.1.2 RESTRAINTS
    • 5.1.2.1 High development costs
  • 5.1.3 OPPORTUNITIES
    • 5.1.3.1 Increased preference for self-administration and home care
    • 5.1.3.2 Rising interest in biosimilars and biologics
    • 5.1.3.3 Market opportunities in emerging economies
    • 5.1.3.4 Development of biocompatible materials for drug delivery systems
  • 5.1.4 CHALLENGES
    • 5.1.4.1 Pricing pressure from governing bodies
    • 5.1.4.2 Risk of needlestick injuries
• 5.2 REGULATORY LANDSCAPE
  • 5.2.1 NORTH AMERICA
    • 5.2.1.1 US
    • 5.2.1.2 Canada
  • 5.2.2 EUROPE
    • 5.2.2.1 Germany
    • 5.2.2.2 Italy
    • 5.2.2.3 France
    • 5.2.2.4 UK
    • 5.2.2.5 Switzerland
  • 5.2.3 ASIA PACIFIC
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 South Korea
    • 5.2.3.5 Australia
  • 5.2.4 LATIN AMERICA
  • 5.2.5 MIDDLE EAST & AFRICA
  • 5.2.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 SUPPLY CHAIN ANALYSIS
  • 5.4.1 PROMINENT COMPANIES
  • 5.4.2 SMALL & MEDIUM-SIZED COMPANIES
  • 5.4.3 END USERS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
  • 5.7.2 AUTOMATED INSULIN DELIVERY (AID)
    • 5.7.2.1 Wearable patches
    • 5.7.2.2 On-body drug delivery systems
    • 5.7.2.3 Needle-free drug delivery systems
    • 5.7.2.4 3D printing
    • 5.7.2.5 Responsive hydrogels
    • 5.7.2.6 Exosomes and extracellular vesicles
    • 5.7.2.7 Polymeric particles and implants
    • 5.7.2.8 Atomic layer deposition
    • 5.7.2.9 Ingestible injectables
    • 5.7.2.10 Ocular drug delivery
  • 5.7.3 COMPLEMENTARY TECHNOLOGIES
    • 5.7.3.1 Pen injectors
    • 5.7.3.2 Prefilled syringes
    • 5.7.3.3 Autoinjector technology
    • 5.7.3.4 Nanotechnology
• 5.8 TRADE ANALYSIS
  • 5.8.1 TRADE ANALYSIS FOR SYRINGES, WITH OR WITHOUT NEEDLES, USED IN MEDICAL, SURGICAL, DENTAL, OR VETERINARY SCIENCES
  • 5.8.2 TRADE ANALYSIS FOR MEDICAMENTS IN MEASURED DOSES, INCLUDING TRANSDERMAL ADMINISTRATION
• 5.9 PATENT ANALYSIS
  • 5.9.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
  • 5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 THREAT OF NEW ENTRANTS
  • 5.10.2 THREAT OF SUBSTITUTES
  • 5.10.3 BARGAINING POWER OF SUPPLIERS
  • 5.10.4 BARGAINING POWER OF BUYERS
  • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.11.2 BUYING CRITERIA
• 5.12 PRICING ANALYSIS
• 5.13 KEY CONFERENCES & EVENTS (2024-2025)
• 5.14 REIMBURSEMENT ANALYSIS
• 5.15 CASE STUDY ANALYSIS
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 UNMET NEEDS IN PHARMACEUTICAL DRUG DELIVERY MARKET
• 5.18 END-USER EXPECTATIONS IN PHARMACEUTICAL DRUG DELIVERY MARKET
• 5.19 AI INTEGRATION IN PHARMACEUTICAL DRUG DELIVERY MARKET

6 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

• 6.1 INTRODUCTION
• 6.2 INJECTABLE DRUG DELIVERY
  • 6.2.1 CONVENTIONAL INJECTION DEVICES
    • 6.2.1.1 Conventional injection devices market, by material
      • 6.2.1.1.1 Glass syringes
        • 6.2.1.1.1.1 Durability and safety to drive adoption
      • 6.2.1.1.2 Plastic syringes
        • 6.2.1.1.2.1 Lower price compared to glass syringes to propel adoption
    • 6.2.1.2 Conventional injection devices market, by product
      • 6.2.1.2.1 Fillable syringes
        • 6.2.1.2.1.1 Ease of use and variable dosing formulations of fillable syringes to drive market
      • 6.2.1.2.2 Prefilled syringes
        • 6.2.1.2.2.1 Improved dose accuracy and increased patient convenience & safety to support usage
    • 6.2.1.3 Conventional injection devices market, by usability
      • 6.2.1.3.1 Reusable syringes
        • 6.2.1.3.1.1 Ease of use, dismantling, and cleaning to support market growth
      • 6.2.1.3.2 Disposable syringes
        • 6.2.1.3.2.1 Low cost and convenience to favor end-user demand
  • 6.2.2 SELF-INJECTION DEVICES
    • 6.2.2.1 Needle-free injectors
      • 6.2.2.1.1 Rapid drug delivery and better reproducibility than invasive drug delivery systems to support market growth
    • 6.2.2.2 Autoinjectors
      • 6.2.2.2.1 Improved patient satisfaction compared to manual injections to drive market
    • 6.2.2.3 Pen injectors
      • 6.2.2.3.1 Need for multi-dose devices to propel adoption
    • 6.2.2.4 Wearable injectors
      • 6.2.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare to support market growth
• 6.3 ORAL DRUG DELIVERY
  • 6.3.1 SOLID ORAL DRUGS
    • 6.3.1.1 Tablets
      • 6.3.1.1.1 Development of mini-tablets to propel market growth
    • 6.3.1.2 Capsules
      • 6.3.1.2.1 Easy absorption of drugs and decreased irritation in GI tract drive capsule usage
    • 6.3.1.3 Oral powders
      • 6.3.1.3.1 Convenience for patients with trouble swallowing other dosage forms to propel usage
    • 6.3.1.4 Pills
      • 6.3.1.4.1 Rising incidence of target ailments to propel market growth
  • 6.3.2 LIQUID ORAL DRUGS
    • 6.3.2.1 Oral syrups
      • 6.3.2.1.1 Ease of administration to drive usage
    • 6.3.2.2 Oral solutions
      • 6.3.2.2.1 Rising preference among geriatric and pediatric patients to support adoption
    • 6.3.2.3 Oral emulsions
      • 6.3.2.3.1 Enhanced solubility, stability, and ease of administration to drive market
    • 6.3.2.4 Oral elixirs
      • 6.3.2.4.1 Rising preference in pediatric cases to drive market
  • 6.3.3 SEMI-SOLID ORAL DRUGS
    • 6.3.3.1 Oral gels
      • 6.3.3.1.1 Controlled drug release benefits to propel usage
    • 6.3.3.2 Oral pastes
      • 6.3.3.2.1 Protection against oxidation and enzymatic hydrolysis to support adoption
• 6.4 TOPICAL DRUG DELIVERY
  • 6.4.1 SEMI-SOLID TOPICAL FORMULATIONS
    • 6.4.1.1 Topical creams
      • 6.4.1.1.1 Variable efficacy to affect end-user adoption
    • 6.4.1.2 Topical gels
      • 6.4.1.2.1 Faster drug release and greater patient acceptability to drive the market for topical gels
    • 6.4.1.3 Topical ointments
      • 6.4.1.3.1 Wide usage in analgesic indications to drive market
    • 6.4.1.4 Topical pastes
      • 6.4.1.4.1 Wide usage in treating/preventing skin irritation to support growth
    • 6.4.1.5 Topical lotions
      • 6.4.1.5.1 Ease of administration of lotions to drive demand
  • 6.4.2 LIQUID TOPICAL FORMULATIONS
    • 6.4.2.1 Topical suspensions
      • 6.4.2.1.1 High bioavailability and controlled onset of action to support adoption
    • 6.4.2.2 Topical emulsions
      • 6.4.2.2.1 Improved spreadability, stability, and controlled release of active ingredients
    • 6.4.2.3 Topical solutions
      • 6.4.2.3.1 Ease of use and ready availability to support market growth
  • 6.4.3 SOLID TOPICAL FORMULATIONS
    • 6.4.3.1 Topical powders
      • 6.4.3.1.1 Rising incidence of skin disorders to drive market
    • 6.4.3.2 Suppositories
      • 6.4.3.2.1 Compatibility and stability to support growth
  • 6.4.4 TRANSDERMAL PRODUCTS
    • 6.4.4.1 Transdermal patches
      • 6.4.4.1.1 Prevention of premature metabolization of drugs to drive market
    • 6.4.4.2 Transdermal gels
      • 6.4.4.2.1 Rapid drug release capabilities to support usage of gels
    • 6.4.4.3 Transdermal sprays
      • 6.4.4.3.1 Simplicity and noninvasive nature to support adoption
• 6.5 OCULAR DRUG DELIVERY
  • 6.5.1 LIQUID OCULAR FORMULATIONS
    • 6.5.1.1 Eye drops
      • 6.5.1.1.1 Rising prevalence of cataracts and other eye diseases to drive market growth
    • 6.5.1.2 Liquid ocular sprays
      • 6.5.1.2.1 Benefits over eye drops to support market growth
  • 6.5.2 SEMI-SOLID OCULAR FORMULATIONS
    • 6.5.2.1 Ocular gels
      • 6.5.2.1.1 High viscosity, prolonged drug release, and ease of drug administration to support market growth
    • 6.5.2.2 Eye ointments
      • 6.5.2.2.1 Safety and efficient administration to drive market
  • 6.5.3 OCULAR DEVICES
    • 6.5.3.1 Ocular inserts
      • 6.5.3.1.1 Support for sustained drug release to drive adoption
    • 6.5.3.2 Drug-coated contact lenses
      • 6.5.3.2.1 Better eyesight offered by lenses and high compliance to drive market
• 6.6 PULMONARY DRUG DELIVERY
  • 6.6.1 METERED-DOSE INHALERS
    • 6.6.1.1 Support for coordinating inhaler actuation and patient breath to drive adoption
  • 6.6.2 DRY POWDER INHALERS
    • 6.6.2.1 Chemical stability of formulations to support usage
  • 6.6.3 NEBULIZERS
    • 6.6.3.1 Jet nebulizers
      • 6.6.3.1.1 Jet nebulizers to account for largest share of nebulizers market
    • 6.6.3.2 Ultrasonic nebulizers
      • 6.6.3.2.1 Ease of use and comfort for patients to propel adoption
    • 6.6.3.3 Soft mist nebulizers
      • 6.6.3.3.1 Rising preference in COPD treatment to propel market
• 6.7 NASAL DRUG DELIVERY
  • 6.7.1 NASAL SPRAYS
    • 6.7.1.1 Applications in relieving nasal congestion, runny nose, itchy nose, and sneezing to support adoption
  • 6.7.2 NASAL DROPS
    • 6.7.2.1 Efficiency over nasal sprays to drive adoption
  • 6.7.3 NASAL GELS
    • 6.7.3.1 Long-lasting relief and reduced irritation to support growth
  • 6.7.4 NASAL POWDERS
    • 6.7.4.1 Absence of preservatives and stability of formulations to support adoption
• 6.8 TRANSMUCOSAL DRUG DELIVERY
  • 6.8.1 ORAL TRANSMUCOSAL FORMULATIONS
  • 6.8.2 BUCCAL DRUG DELIVERY
    • 6.8.2.1 Applications in local and systematic therapies to drive adoption
    • 6.8.2.2 Sublingual drug delivery
      • 6.8.2.2.1 High rate of adoption to propel usage
  • 6.8.3 OTHER TRANSMUCOSAL FORMULATIONS
    • 6.8.3.1 Rectal drug delivery
      • 6.8.3.1.1 High vascularization to support rapid drug absorption
    • 6.8.3.2 Vaginal drug delivery
      • 6.8.3.2.1 Higher permeability and drug stability to drive market
• 6.9 IMPLANTABLE DRUG DELIVERY
  • 6.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY
    • 6.9.1.1 Targeted drug delivery benefits to propel market
  • 6.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY
    • 6.9.2.1 Need for better diagnostic monitoring and body fluid transportation to favor market growth

7 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 INFECTIOUS DISEASES
  • 7.2.1 HIGH BURDEN OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
• 7.3 CANCER
  • 7.3.1 GROWING INCIDENCE OF CANCER TO ENSURE DEMAND FOR THERAPY
• 7.4 CVD
  • 7.4.1 INCREASING PREVALENCE AND INCREASING INNOVATION IN DRUG DELIVERY TECHNOLOGIES TO PROPEL MARKET GROWTH
• 7.5 DIABETES
  • 7.5.1 EMERGENCE OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH
• 7.6 RESPIRATORY DISEASES
  • 7.6.1 HIGH PREVALENCE OF ASTHMA AND COPD TO DRIVE ADOPTION OF PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
• 7.7 CNS DISORDERS
  • 7.7.1 WIDE USAGE OF ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS TO DRIVE MARKET
• 7.8 AUTOIMMUNE DISEASES
  • 7.8.1 AUTOIMMUNE DISEASES TO REGISTER HIGHEST GROWTH
• 7.9 OTHER APPLICATIONS
  • 7.9.1 OPHTHALMIC DISORDERS
  • 7.9.2 ENDOCRINE DISORDERS

8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE

• 8.1 INTRODUCTION
• 8.2 HOSPITALS
  • 8.2.1 HOSPITALS TO HOLD LARGEST MARKET SHARE THROUGHOUT FORECAST PERIOD
• 8.3 AMBULATORY SURGERY CENTERS/CLINICS
  • 8.3.1 INCREASING PREFERENCE FOR AMBULATORY CARE TO FUEL DEMAND FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
• 8.4 HOME CARE SETTINGS
  • 8.4.1 HOME CARE SETTINGS TO REGISTER HIGHEST GROWTH RATE
• 8.5 DIAGNOSTIC CENTERS
  • 8.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
• 8.6 OTHER FACILITIES OF USE

9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 US
    • 9.2.1.1 US to dominate North American pharmaceutical drug delivery market
  • 9.2.2 CANADA
    • 9.2.2.1 Government support for research and rising prevalence of chronic diseases to drive market
• 9.3 EUROPE
  • 9.3.1 GERMANY
    • 9.3.1.1 Growing focus of pharmaceutical companies on developing innovative drug delivery products to drive market
  • 9.3.2 FRANCE
    • 9.3.2.1 Presence of leading pharmaceutical companies and rising prevalence of chronic diseases to drive market
  • 9.3.3 ITALY
    • 9.3.3.1 Increasing focus on clinical research and growing popularity of branded drugs to drive demand
  • 9.3.4 UK
    • 9.3.4.1 Increasing incidence and prevalence of chronic and infectious diseases to drive market
  • 9.3.5 SPAIN
    • 9.3.5.1 Increase in biologics production to support market growth
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
    • 9.4.1.1 High diabetes incidence and favorable government initiatives to drive market
  • 9.4.2 JAPAN
    • 9.4.2.1 Favorable government initiatives and increased geriatric population to drive market growth in Japan
  • 9.4.3 INDIA
    • 9.4.3.1 Growing generic demand and rising government initiatives to drive market
  • 9.4.4 AUSTRALIA
    • 9.4.4.1 Favorable government initiatives and outlook for pharma sector to support growth
  • 9.4.5 SOUTH KOREA
    • 9.4.5.1 Growing pharmaceutical segment to support demand for delivery technologies
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 BRAZIL
    • 9.5.1.1 Investments and government support to attract multinational pharma companies to Brazil
  • 9.5.2 MEXICO
    • 9.5.2.1 Growth and diversification in Mexico's pharmaceutical exports to drive market
  • 9.5.3 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 GCC COUNTRIES
    • 9.6.1.1 Rising healthcare expenditure to drive market growth
  • 9.6.2 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET
• 10.3 REVENUE ANALYSIS
• 10.4 MARKET SHARE ANALYSIS
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Route of administration footprint
    • 10.5.5.3 Region footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 10.7 VALUATION & FINANCIAL METRICS
  • 10.7.1 FINANCIAL METRICS
  • 10.7.2 COMPANY VALUATION
• 10.8 BRAND/PRODUCT COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES & APPROVALS
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS
  • 10.9.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 JOHNSON & JOHNSON SERVICES, INC.
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product approvals
      • 11.1.1.3.2 Deals
      • 11.1.1.3.3 Other developments
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 NOVARTIS AG
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product approvals
      • 11.1.2.3.2 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Right to win
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses and competitive threats
  • 11.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product approvals
      • 11.1.3.3.2 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses and competitive threats
  • 11.1.4 PFIZER INC.
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Product approvals
      • 11.1.4.3.2 DEALS
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Right to win
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses and competitive threats
  • 11.1.5 BECTON, DICKINSON AND COMPANY
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product launches
      • 11.1.5.3.2 Other developments
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Right to win
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses and competitive threats
  • 11.1.6 GLAXOSMITHKLINE PLC
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product approvals
      • 11.1.6.3.2 Deals
      • 11.1.6.3.3 Other developments
  • 11.1.7 MERCK & CO., INC.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product approvals
      • 11.1.7.3.2 Deals
  • 11.1.8 SANOFI
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product approvals
      • 11.1.8.3.2 Deals
  • 11.1.9 BAYER AG
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Product approvals
      • 11.1.9.3.2 Deals
      • 11.1.9.3.3 Expansions
  • 11.1.10 AMGEN, INC.
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Product approvals
      • 11.1.10.3.2 Deals
  • 11.1.11 ABBVIE INC.
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Product launches & approvals
      • 11.1.11.3.2 Deals
      • 11.1.11.3.3 Expansions
  • 11.1.12 GENMAB A/S
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Product approvals
      • 11.1.12.3.2 Deals
  • 11.1.13 GILEAD SCIENCES, INC.
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product approvals
      • 11.1.13.3.2 Deals
      • 11.1.13.3.3 Other developments
  • 11.1.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Product approvals
      • 11.1.14.3.2 Deals
  • 11.1.15 ASTRAZENECA
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Product approvals
      • 11.1.15.3.2 Deals
  • 11.1.16 ELI LILLY AND COMPANY
    • 11.1.16.1 Business overview
    • 11.1.16.2 Products offered
    • 11.1.16.3 Recent developments
      • 11.1.16.3.1 Product approvals
      • 11.1.16.3.2 Deals
      • 11.1.16.3.3 Expansions
  • 11.1.17 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 11.1.17.1 Business overview
    • 11.1.17.2 Products offered
    • 11.1.17.3 Recent developments
      • 11.1.17.3.1 Product approvals & launches
      • 11.1.17.3.2 Deals
• 11.2 OTHER PLAYERS
  • 11.2.1 NOVO NORDISK A/S
  • 11.2.2 GLENMARK PHARMACEUTICALS LTD.
  • 11.2.3 VIATRIS INC
  • 11.2.4 BRISTOL-MYERS SQUIBB COMPANY
  • 11.2.5 SANDOZ GROUP AG
  • 11.2.6 GERRESHEIMER AG
  • 11.2.7 BOSTON SCIENTIFIC CORPORATION
  • 11.2.8 CMP PHARMA
  • 11.2.9 RUSAN PHARMA

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS